jcm-logo

Journal Browser

Journal Browser

Breast Cancer: Symptoms, Types, Causes & Treatment

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Obstetrics & Gynecology".

Deadline for manuscript submissions: 20 February 2026 | Viewed by 70

Special Issue Editors


E-Mail Website
Guest Editor
Department of Plastic and Reconstructive Surgery, The Ohio State University, Columbus, OH, USA
Interests: microsurgery; breast cancer; lymphedema; super-microsurgery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Division of Surgical Oncology, Department of Surgery, College of Medicine, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
Interests: breast cancer; surgical oncology; lymphedema

Special Issue Information

Dear Colleagues,

This special journal issue will focus on the diverse experiences of breast cancer treatment and survivorship across the age spectrum, examining how age at diagnosis shapes clinical decision-making, treatment outcomes, and quality of life post-treatment. From the unique reproductive and psychosocial concerns of young women to the comorbidities and functional limitations faced by older adults, age plays a critical role in influencing therapeutic approaches, patient priorities, and survivorship trajectories. In this Special Issue, titled “Breast Cancer: Symptoms, Types, Causes & Treatment”, we seek to provide insights into the latest research in various factors contributing to age-related disparities in care and outcomes, with the goal of advancing more tailored, equitable strategies in breast cancer management across the lifespan.

Dr. Min-Jeong Cho
Dr. Sara P. Myers
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ductal carcinoma in situ (DCIS)
  • breast cancer
  • breast cancer prevention
  • minimally invasive surgery
  • innovative imaging technologies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

15 pages, 1884 KB  
Protocol
Preliminary Efficacy/Feasibility Study of a Breast Cancer-Related Lymphedema Prospective Screening and Early Intervention Program at the Dana-Farber Brigham Cancer Center
by Sara P. Myers, Jacob M. Jasper, Tessa Higgins, Angela Serig, Amanda C. Faust, Lila J. Tappan, Faina Nakhlis, Erin M. Taylor, Shailesh Agarwal, Elizabeth A. Mittendorf and Tari A. King
J. Clin. Med. 2025, 14(19), 7051; https://doi.org/10.3390/jcm14197051 (registering DOI) - 6 Oct 2025
Abstract
Background: Breast cancer-related lymphedema (BCRL) is a common and debilitating treatment-related adverse event that can profoundly impact quality of life and financial well-being. Although prospective surveillance and early intervention for BCRL have been shown to reduce the incidence and severity of this [...] Read more.
Background: Breast cancer-related lymphedema (BCRL) is a common and debilitating treatment-related adverse event that can profoundly impact quality of life and financial well-being. Although prospective surveillance and early intervention for BCRL have been shown to reduce the incidence and severity of this chronic condition, diagnostic accuracy of screening, programmatic utilization and efficacy vary widely. We describe the protocol for the BCRL Prospective Surveillance Model (PSM) and Early Intervention Program at the Dana-Farber Brigham Cancer Center that aims to address these issues by augmenting arm measurements (standard of care) with use of patient-reported outcome metrics (PROMs). Methods: Women with newly diagnosed stage I-III breast cancer at high risk for developing BCRL based on tumor and treatment characteristics are eligible for inclusion in our PSM care pathway, which uses both the Breast Cancer and Lymphedema Symptom Experience Index PROMs and arm measurements for screening. Screening begins prior to the initiation of neoadjuvant therapy and continues at regular intervals postoperatively. A positive screen, defined as new patient-reported arm swelling/heaviness and/or relative volume change (RVC) ≥ 5% in the affected limb, triggers consideration for multidisciplinary early intervention. Analysis: The BCRL detection rate will be compared to years previous to protocol development. PSM feasibility will be determined according to the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. Efficacy of the PSM will be gauged by comparing change in patient-reported outcomes of interest and arm volume measurement pre and post early intervention. Feasibility will be determined by calculating the percentage of PSM-eligible individuals who complete all PSM activities in a 1-year span. Characteristics of participants versus non-participants in the target population will be compared. Furthermore, 1:1 semi-structured interviews with enrolled patients will be performed to understand facilitators and barriers to implementation. Conclusions: The findings from this study will be used to develop a standardized approach to PSM and early intervention that can be adapted to both resource-modest and resource-abundant healthcare infrastructures. Full article
(This article belongs to the Special Issue Breast Cancer: Symptoms, Types, Causes & Treatment)
Show Figures

Figure 1

Back to TopTop